Published September 5, 2014 | Version v1
Journal article

Immunoadjuvant activity of the nanoparticles' surface modified with mannan

  • 1. Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK (Canada)
  • 2. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada, T6G 2E1 (Canada)

Description

Mannan (MN) is the natural ligand for mannose receptors, which are widely expressed on dendritic cells (DCs). The purpose of this study was to assess the effect of formulation parameters on the immunogenicity of MN-decorated poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) in terms of their ability to stimulate DC phenotypic as well as functional maturation. For this purpose, NPs were formulated from either ester-terminated or COOH-terminated PLGA. Incorporation of MN in NPs was achieved through encapsulation, physical adsorption or chemical conjugation. Murine bone marrow derived DCs (BMDCs) were treated with various NP formulations and assessed for their ability to up-regulate DC cell surface markers, secrete immunostimulatory cytokines and to activate allogenic T cell responses. DCs treated with COOH-terminated PLGA-NPs containing chemically conjugated MN (MN-Cov-COOH) have shown superior performance in improving DC biological functions, compared to the rest of the formulations tested. This may be attributed to the higher level of MN incorporation in the former formulation. Incorporation of MN in PLGA NPs through chemical conjugation can lead to enhanced DC maturation and stimulatory function. This strategy may be used to develop more effective PLGA-based vaccine formulations. (paper)

Availability note (English)

Available from http://dx.doi.org/10.1088/0957-4484/25/35/355101

Additional details

Publishing Information

Journal Title
Nanotechnology (Print)
Journal Volume
25
Journal Issue
35
Journal Page Range
[13 p.]
ISSN
0957-4484